Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

Multidrug-resistant tuberculosis (MDR) is perceived as a growing hazard to human health worldwide. Judgments about the true scale of the problem, and strategies for containing it, need to come from a balanced appraisal of the epidemiological evidence. We conclude in this review that MDR is, and will probably remain, a locally severe problem; that epidemics can be prevented by fully exploiting the potential of standard short-course chemotherapy (SCC) based on cheap and safe first-line drugs; and that best-practice SCC may even reduce the incidence of MDR where it has already become endemic. On the basis of the available, imperfect data, we recommend a three-part response to the threat of MDR: widespread implementation of SCC as the cornerstone of good tuberculosis control, improved resistance testing and surveillance, and the careful introduction of second-line drugs after a sound evaluation of cost, effectiveness, and feasibility.

[1]  D. van Soolingen,et al.  Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements , 2001, Journal of internal medicine.

[2]  N. Binkin,et al.  Determinants of drug-resistant tuberculosis: analysis of 11 countries. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  R. Reves,et al.  Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P E Fine,et al.  The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers , 1998, Epidemiology and Infection.

[5]  C. Dye,et al.  Will tuberculosis become resistant to all antibiotics? , 2001, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[6]  I. Orme,et al.  Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice , 1995, Infection and immunity.

[7]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[8]  D. van Soolingen,et al.  Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. , 1999, The Journal of infectious diseases.

[9]  S. Svenson,et al.  Spread of Drug-Resistant Pulmonary Tuberculosis in Estonia , 2001, Journal of Clinical Microbiology.

[10]  S. Blower,et al.  The intrinsic transmission dynamics of tuberculosis epidemics , 1995, Nature Medicine.

[11]  T. Whittam,et al.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Snider,et al.  Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. , 2015, The American review of respiratory disease.

[13]  D. van Soolingen,et al.  Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. , 2000, Emerging infectious diseases.

[14]  Jim Y. Kim,et al.  Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus” , 1998, BMJ.

[15]  D. van Soolingen,et al.  Mycobacterium tuberculosis Beijing genotype strains associated with febrile response to treatment. , 2001, Emerging infectious diseases.

[16]  N. Nagelkerke,et al.  Analysis of tuberculosis transmission between nationalities in the Netherlands in the period 1993-1995 using DNA fingerprinting. , 1998, American journal of epidemiology.

[17]  P. Small,et al.  Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. , 2000, Archives of internal medicine.

[18]  M. Pagano,et al.  Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  S. Blower,et al.  Control Strategies for Tuberculosis Epidemics: New Models for Old Problems , 1996, Science.

[20]  A. Vernon,et al.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid , 1999, The Lancet.

[21]  Rajesh K. Gupta,et al.  Responding to Market Failures in Tuberculosis Control , 2001, Science.

[22]  K. Kam,et al.  Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  M. Hazbón,et al.  Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  C. Dye,et al.  Rational 'DOTS plus' for the control of MDR-TB. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  M. Iseman,et al.  PITFALLS IN THE CARE OF PATIENTS WITH TUBERCULOSIS: COMMON ERRORS AND THEIR ASSOCIATION WITH THE ACQUISITION OF DRUG RESISTANCE , 1993, JAMA.

[26]  Christopher Dye,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.

[27]  J. Davies,et al.  Bacteria on the rampage , 1996, Nature.

[28]  M. Pavlic,et al.  Mycobacterium tuberculosis isolates of Beijing genotype in Thailand. , 2001, Emerging infectious diseases.

[29]  J. T. Crawford,et al.  A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. , 1996, JAMA.

[30]  P. Sonnenberg,et al.  Tuberculosis control and molecular epidemiology in a South African gold-mining community , 2000, The Lancet.

[31]  Annelies Van Rie,et al.  Analysis for a Limited Number of Gene Codons Can Predict Drug Resistance of Mycobacterium tuberculosis in a High-Incidence Community , 2001, Journal of Clinical Microbiology.

[32]  D. Maher,et al.  Guidelines for the Management of Drug-resistant Tuberculosis , 1997 .

[33]  L. Karasulu,et al.  The treatment of multidrug-resistant tuberculosis in Turkey. , 2001, The New England journal of medicine.

[34]  M. Perkins,et al.  Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  G. Turner,et al.  Neonatal screening for cystic fibrosis , 2000, The Lancet.